Evolutionary rescue of phosphomannomutase deficiency in yeast models of human disease

Ryan C. Vignogna, Mariateresa Allocca, Maria Monticelli, Joy W. Norris, Richard Steet, Ethan O. Perlstein, Giuseppina Andreotti, Gregory I. Lang

1Department of Biological Sciences, Lehigh University, Bethlehem PA, USA
2Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania “Luigi Vanvitelli”, Caserta, Italy
3Institute of Biomolecular Chemistry, National Research Council of Italy, Pozzuoli, Italy
4Department of Biology, University of Napoli “Federico II”, Napoli, Italy
5Research Division, Greenwood Genetic Center, Greenwood SC, USA
6Perlara PBC, Berkeley CA, USA

†Present address: Department of Molecular Biology and Genetics, Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, NY, USA

*Authors for correspondence:
gandreotti@icb.cnr.it
glang@lehigh.edu

ORCID:
0000-0001-5943-6464 (RCV)
0000-0003-3693-2515 (MA)
0000-0003-3136-2138 (MM)
0000-0002-0852-6870 (JWN)
0000-0002-0975-4963 (RS)
0000-0002-4734-4391 (EOP)
0000-0002-1594-0156 (GA)
0000-0002-7931-0428 (GIL)
ABSTRACT

The most common cause of human congenital disorders of glycosylation (CDG) are mutations in the phosphomannomutase gene PMM2, which affect protein N-linked glycosylation. The yeast gene SEC53 encodes a homolog of human PMM2. We evolved 384 populations of yeast harboring one of two human-disease-associated alleles, sec53-V238M and sec53-F126L, or wild-type SEC53. We find that after 1,000 generations, most populations compensate for the slow-growth phenotype associated with the sec53 human-disease-associated alleles. Through whole-genome sequencing we identify compensatory mutations, including known SEC53 genetic interactors. We observe an enrichment of compensatory mutations in other genes whose human homologs are associated with Type 1 CDG, including PGM1, which encodes the minor isoform of phosphoglucomutase in yeast. By genetic reconstruction, we show that evolved pgm1 mutations are dominant and allele-specific genetic interactors that restore both protein glycosylation and growth of yeast harboring the sec53-V238M allele. Finally, we characterize the enzymatic activity of purified Pgm1 mutant proteins. We find that reduction, but not elimination, of Pgm1 activity best compensates for the deleterious phenotypes associated with the sec53-V238M allele. Broadly, our results demonstrate the power of experimental evolution as a tool for identifying genes and pathways that compensate for human-disease associated alleles.
INTRODUCTION

Protein glycosylation is an important cotranslational and posttranslational modification involving the attachment of glycans to polypeptides. These glycans play vital roles in protein folding, stability, activity, and transport (Varki, 2017). Glycosylation is one of the most abundant protein modifications, with evidence indicating that over 50% of human proteins are glycosylated (Roth et al., 2012; Wong, 2005). Despite this, we lack a global understanding of the complex pathologies involving protein glycosylation.

Congenital disorders of glycosylation (CDG) are a group of inherited metabolic disorders arising from defects in the protein glycosylation pathway, including \(N\)-linked glycosylation, \(O\)-linked glycosylation, and lipid/glycosylphosphatidylinositol anchor biosynthesis (Chang et al., 2018). \(N\)-linked CDG are further categorized into two groups based on the affected process: synthesis and transfer of glycans (Type 1) or processing of protein-bound glycans (Type 2) (Aebi et al., 1999). Mutations in the human phosphomannomutase 2 gene (\(PMM2\)) cause Type 1 CDG and are the most common cause of CDG (Ferreira et al., 2018). PMM2 forms a homodimer and catalyzes the interconversion of mannose-6-phosphate and mannose-1-phosphate (EC 5.4.2.8). Mannose-1-phosphate is then converted to GDP-mannose, a required substrate for \(N\)-linked glycosylation glycosyltransferases.

Two of the most common pathogenic \(PMM2\) variants found in humans are p.Val231Met and p.Phe119Leu. The V231M protein is less stable and exhibits defects in protein folding (Citro et al., 2018; Silvaggi et al., 2006), whereas the F119L protein is stable but exhibits dimerization defects (Andreotti et al., 2015; Kjaergaard et al., 1999; Pirard et al., 1999). The budding yeast \(Saccharomyces cerevisiae\) contains a homologous phosphomannomutase enzyme encoded by the gene \(SEC53\). \(SEC53\) is essential in yeast and expression of human \(PMM2\) rescues lethality (Hansen et al., 1997; Lao et al., 2019). Previously, Lao et al. (2019) constructed strains harboring the yeast-equivalent mutations of the most common human disease-associated \(PMM2\) alleles including V231M (\(sec53\)-V238M) and F119L (\(sec53\)-F126L).

Using experimental evolution, we sought to identify compensatory mutations able to overcome glycosylation-deficiency. Previous studies have used experimental evolution of compromised organisms, to study evolutionary outcomes and identify compensatory mutations (Harcombe et al., 2009; Helsen et al., 2020; Laan et al., 2015; Michel et al., 2017; Moser et al., 2017; Szamecz et al., 2014). Experimental evolution allows for a more robust approach than traditional suppressor screens, enabling the identification of weak suppressors and compensatory interactions between multiple mutations (Cooper, 2018; LaBar et al., 2020).
Here we present a 1,000-generation evolution experiment of yeast models of PMM2-CDG. We evolved 96 populations of yeast with wild-type SEC53, 192 populations with the sec53-V238M allele, and 96 populations with the sec53-F126L allele for 1,000 generations. We sequenced 188 evolved clones to identify mutations that arose specifically in the populations harboring the sec53 human-disease-associated alleles. We find an overrepresentation of mutations in genes whose human homologs are other Type 1 CDG genes, including PGM1 (the minor isoform of phosphoglucomutase), the most commonly mutated gene in our experiment. We show that evolved mutations in PGM1 restore protein N-linked glycosylation and alleviate the slow-growth phenotype caused by the sec53-V238M disease-associated allele. We performed genetic and biochemical characterization of the pgm1 mutations and show that these mutations are dominant and allele-specific SEC53 genetic-interactors.

RESULTS

Experimental evolution improves growth of yeast models of PMM2-CDG

Mutations in the phosphomannomutase 2 gene, PMM2, are the most common cause of congenital disorders of glycosylation (CDG). Previously Lao et al., 2019 constructed yeast models of PMM2-CDG by making the yeast-equivalent mutations for five human-disease-associated alleles in SEC53, the yeast ortholog of PMM2. These strains have growth rate defects that correlate with enzymatic activity and promoter strength. Increasing expression levels of the mutant sec53 alleles two-fold, by replacing the endogenous promoter (pSEC53) with the ACT1 promoter (pACT1), modestly improves the growth rate of sec53 disease-associated alleles (Figure 1A).

We chose to focus on sec53-V238M and sec53-F126L because they are two of the most common disease alleles in humans and because the mutations have distinct and well-characterized effects on protein structure and function (Figure 1A) (Andreotti et al., 2015; Briso-Montiano et al., 2022; Citro et al., 2018; Kjaergaard et al., 1999; Pirard et al., 1999; Silvaggi et al., 2006). We evolved 96 haploid populations of each mutant sec53 genotype (pSEC53-sec53-V238M, pACT1-sec53-V238M, pACT1-sec53-F126L) and 48 haploid populations of each wild-type SEC53 genotype (pSEC53-SEC53-WT, pACT1-SEC53-WT) for 1,000 generations in rich glucose medium (Figure 1B). Strains with the pSEC53-sec53-F126L allele grew too slowly to keep up with a 1:2^10 dilution every 24 hours. Every 50 generations we measured culture density (single time-point OD600) for each population as a proxy for growth rate (Figure 1C; Figure 1 — figure supplement 1).
Populations with the pACT1-sec53-V238M allele show a range of dynamics, with some populations reaching maximum saturation (OD$_{600}$ ≈ 1.0) early in the experiment, while some do not even by Generation 1,000 (Figure 1C). Three pACT1-sec53-V238M populations went extinct before Generation 200. While saturation levels of pACT1-sec53-F126L populations also increased over the course of the evolution experiment, none reached an OD$_{600}$ close to 1.0, indicating that these populations are likely less-fit than the evolved pACT1-sec53-V238M populations. Each pSEC53-sec53-V238M population started the evolution experiment with growth rates comparable to SEC53-WT populations, indicating compensatory mutation(s) likely arose in the starting inocula (Figure 1 — figure supplement 1). We therefore exclude these populations from subsequent analyses. Together, our data show that the PMM2-CDG yeast models acquired compensatory mutations throughout the evolution experiment and that the extent of compensation depends on the specific disease-associated allele.

Putative compensatory mutations are enriched for other Type 1 CDG-associated homologs

To identify the compensatory mutations in our evolved populations, we sequenced single clones from 188 populations isolated at Generation 1,000 to an average sequencing depth of ~50x. These included 91 pACT1-sec53-V238M clones, 36 pACT1-sec53-F126L clones, 32 pSEC53-SEC53-WT clones, 11 pACT1-SEC53-WT clones, and 18 of the initially-suppressed pSEC53-sec53-V238M clones (Supplementary File 1). Autodiploids are a common occurrence in our experimental system (Fisher et al., 2018; Johnson et al., 2021). We attempted to avoid sequencing autodiploids by screening our evolved populations for sensitivity to benomyl, an antifungal agent that inhibits growth of S. cerevisiae diploids more severely than haploids (Venkataram et al., 2016).

We find that the average number of de novo mutations (SNPs and small indels) varied between SEC53 genotypes, with the pACT1-sec53-F126L clones accruing more mutations per clone (8.14 ± 1.00, 95% CI) compared to pACT1-sec53-V238M (5.76 ± 0.54) and SEC53-WT clones (combined pSEC53-SEC53-WT and pACT1-SEC53-WT) (6.49 ± 0.90) (Figure 2 — figure supplement 1). Despite screening for benomyl sensitivity, most of the sequenced clones (131/188) appear to be autodiploids, with evidence of multiple heterozygous loci. In addition, we detect several copy number variants and aneuploidies shared between independent populations (Figure 2 — source data 1, 2).

We identified putative adaptive targets of selection as genes with more mutations than expected by chance across replicate clones. Some of these common targets of selection are not
specific to sec53. For example, mutations in negative regulators of Ras (IRA1 and IRA2) are found in clones from each experimental group and are also observed in other laboratory evolution experiments across a wide range of conditions (Figure 2A) (Fisher et al., 2018; Gresham and Hong, 2014; Johnson et al., 2021; Kvitek and Sherlock, 2013; Lang et al., 2013; Venkataram et al., 2016).

We identified putative sec53-compensatory targets as genes mutated exclusively in pACT1-sec53-V238M and/or pACT1-sec53-F126L populations (Figure 2A). The most frequently mutated genes among pACT1-sec53-F126L clones are common targets in other evolution experiments such as IRA1, IRA2, and KRE6, suggesting that mutations capable of compensating for Sec53-F126L dimerization defects are rare or not easily accessible. In contrast, while recurrently mutated genes in pACT1-sec53-V238M populations include common targets, we also identified a number of unique targets of selection, most notably in homologs of other Type 1 CDG-associated genes. We find an enrichment of mutations in CDG homologs in pACT1-sec53-V238M clones (Figure 2B; Figure 2 — source data 3).

Across all sequenced populations we identified ~620 nonsynonymous mutations. As there are nearly 6,000 yeast genes, the probability of any given gene receiving even a single nonsynonymous mutation is low. We are therefore well-powered to detect enrichment of mutations, but underpowered to detect depletion of mutations. To gain statistical power we aggregated our SEC53-WT data with three other large data sets using similar strains and propagation regimes (Fisher et al., 2018; Johnson et al., 2021; Lang et al., 2013). In this aggregate dataset, we observe a statistically-significant depletion of mutations in Type 1 CDG homologs, suggesting that they are typically under purifying selection in experimental evolution (Figure 2B).

One of the CDG homologs, PGM1, is the most frequently mutated gene among pACT1-sec53-V238M clones. PGM1 encodes the minor isoform of phosphoglucomutase in yeast (Bevan and Douglas, 1969). We only find PGM1 mutations in pACT1-sec53-V238M populations which suggests their compensatory effects are unique to the sec53-V238M mutation and not glycosylation-deficiency in general. Each of the five mutations in PGM1 are missense mutations, rather than frameshift or nonsense. This is consistent with selection acting on alteration-of-function rather than loss-of-function (posterior probability of non-loss-of-function = 0.96, see Methods).

To identify the compensatory mutation(s) that arose prior to the start of the evolution experiment in the initially-suppressed pSEC53-sec53-V238M populations, we analyzed the 18 sequenced clones. For each clone, we find both wild-type SEC53 and sec53-V238M alleles
among sequencing reads. This could result from integration or maintenance of the covering plasmid. No sequencing reads align to the URA3 locus of our reference genome, suggesting that the plasmid marker was lost, as expected following counterselection.

**Compensatory mutations restore growth**

In order to validate putative compensatory mutations we reconstructed evolved mutations in PGM1 and ALG9, two genes whose human homologs are implicated in Type 1 CDG (Frank et al., 2004; Timal et al., 2012). These heterozygous evolved mutations were constructed in a homozygous pACT1-sec53-V238M diploid background (note that although each pgm1 and alg9 mutation assayed here arose in haploid-founded populations, they arose as heterozygous mutations in autodiploids). We quantified the fitness effect of each mutation using a flow cytometry-based fitness assay, competing the reconstructed strains against a fluorescently-labeled, diploid version of the pACT1-SEC53-WT ancestor.

The pACT1-sec53-V238M ancestor has a fitness deficit of -25.86 ± 2.3% (95% CI) relative to wild-type. We find that each of the five evolved pgm1 mutations is compensatory in the pACT1-sec53-V238M background. The fitness effects of the sec53/pgm1 double-mutants range between -19.10 ± 1.07% and -9.84 ± 0.77% (i.e., the pgm1 mutations confer a fitness benefit between 6.76% and 16.02% in the pACT1-sec53-V238M background) (Figure 3A). We also find that the evolved alg9-S230R mutation is compensatory, as the sec53/alg9 double-mutant has a fitness effect of -17.89 ± 0.59% (Figure 3 — figure supplement 1). We compared the fitness of these reconstructed double-mutants to the fitness of the evolved clones which carry 3-9 additional SNPs. In each case the evolved clones were more fit than the reconstructed strain, except for the evolved clone containing the pgm1-D295N mutation (Figure 3 — figure supplement 1). Thus, while the alg9 and pgm1 mutations compensate for the sec53-V238M defect, other mutations contribute to the overall fitness of these evolved clones.

We constructed and assayed the fitness effects of the pgm1 mutations in diploid pACT1-sec53-F126L and pACT1-SEC53-WT backgrounds. Each pACT1-sec53-F126L strain was too quickly outcompeted by the reference strain to measure fitness, suggesting that the compensatory effects of the evolved pgm1 mutations are specific for the sec53-V238M mutation or any fitness improvements in the pACT1-sec53-F126L background are too minimal to detect. Each pgm1 mutation is nearly neutral in the pACT1-SEC53-WT background (Figure 3 — figure supplement 2).

To determine if loss-of-function (LOF) of PGM1 would phenocopy evolved mutations, we deleted one copy of PGM1 (pgm1Δ) in the diploid pACT1-sec53-V238M background and again
measured fitness. We find that the heterozygous pgm1Δ mutation improves fitness (-15.28 ± 0.76%), indicating that LOF of PGM1 is compensatory in the conditions of the evolution experiment (Figure 3A). It is not immediately clear, then, why we only identify missense mutations in PGM1. Each of the mutated Pgm1 residues are located around the active site of the enzyme, based on predicted protein structure (Jumper et al., 2021; Stiers and Beamer, 2018). It could be that the evolved pgm1 mutations are loss-of-function given this clustering but maintaining protein expression provides an ancillary benefit. To account for this possibility, we constructed a catalytically-dead allele of PGM1 by mutating the enzyme’s catalytic serine (pgm1-S120A) (Stiers et al., 2017a). We find that pgm1-S120A improves pACT1-sec53-V238M fitness (-13.32 ± 0.88%) and this does not significantly differ from pgm1Δ (Figure 3A), indicating that PGM1 LOF is compensatory regardless of if that arises from loss of coding sequence or enzyme activity. We also measured fitness of homozygous pgm1 mutations (Figure 3 — figure supplement 3). In all cases the fitness effect of heterozygous and homozygous pgm1 mutants are not substantially different from each other, indicating that, by this assay, the evolved pgm1 mutations are dominant in the pACT1-sec53-V238M background, as are the pgm1Δ and pgm1-S120A mutations.

Compensatory mutations restore protein glycosylation

We have established that pgm1 mutations compensate for the growth rate defect of the sec53-V238M allele. To determine whether the evolved pgm1 mutants also compensate for the molecular defects in N-linked glycosylation we examined two representative yeast glycoproteins, invertase and carboxypeptidase Y (CPY), in our reconstructed pgm1 strains. Invertase forms both a non-glycosylated homodimer (120 kDa) and a secreted homodimer that is heavily glycosylated (approximate range of 140-270 kDa) (Gascón et al., 1968; Zeng and Biemann, 1999). Mature CPY only exists in its glycosylated form, with a molecular weight of 61 kDa (Hasilik and Tanner, 1978).

The ancestral pACT1-sec53-V238M strain shows underglycosylation of invertase and CPY. We find a reduced abundance of the higher-molecular-weight glycosylated form of invertase and mature CPY, accompanied by the appearance of underglycosylated forms of these proteins (Figure 3B). We find that evolved pgm1 mutations, pgm1Δ, and pgm1-S120A each restore glycosylation of these proteins to near-wild-type levels (Figure 3B, Figure 3 — figure supplements 4,5). We do not observe rescue of protein glycosylation in pACT1-sec53-F126L strains carrying pgm1 mutations (Figure 3 — figure supplement 6). Together, these
suggest that *pgm1*-mediated rescue of pACT1-sec53-V238M fitness is due to restoration of protein glycosylation and the effect is specific for the pACT1-sec53-V238M background.

**Compensatory PGM1 mutations are dominant suppressors of sec53-V238M**

To further demonstrate that *pgm1*-mediated compensation is specific for sec53-V238M, we performed a genetic analysis by dissecting tetrads from strains that are heterozygous for both sec53 and *pgm1*. In the absence of a compensatory mutation, we expect 50% large colonies and all tetrads showing a 2:2 segregation of colony size due to the single segregating locus (SEC53/sec53). However, if an evolved mutation is compensatory then we expect 75% large colonies with three types of segregation patterns: 2:2, 3:1, and 4:0, large to small colonies, respectively. These three segregation patterns are expected to follow a 1:4:1 ratio assuming no genetic linkage (Figure 4A). For each genetic test, we dissected ten tetrads and performed a log likelihood test to determine whether the segregation pattern is more consistent with genetic suppression than non-suppression (Figure 4 — source data 1).

We find each of the evolved *pgm1* mutations compensates for the V238M allele of SEC53 (Figure 4 — figure supplement 1). For example, dissections of a strain heterozygous for pACT1-sec53-V238M and *pgm1*-T521K show 78% large colonies (one 4:0 and nine 3:1, with a log likelihood ratio of 27.6, Figure 4B). These genetic tests corroborate the results from the fitness assays by showing that all five evolved *pgm1* mutations, the *pgm1Δ* and *pgm1*-S120A mutations, as well as the evolved *alg9* mutation all suppress sec53-V238M (Figure 4 — figure supplement 1). We next assayed each of the *pgm1* mutations in a sec53-F126L background. In contrast to the fitness assays, we find several *pgm1* alleles (T521K, D295N, S120A, and *pgm1Δ*) that suppress sec53-F126L (Figure 4 — figure supplement 1). It is worth noting, however, that the degree of compensation is less than in the sec53-V238M background based on colony sizes.

To test if *pgm1* mutations are dominant, we integrated a second wild-type copy of *PGM1* to each of the strains such that each haploid spore will contain either two wild-type copies of *PGM1* (*PGM1::PGM1*) or both wild-type *PGM1* and mutant *pgm1* (*PGM1::pgm1*). We find that the five evolved *pgm1* mutations and *pgm1*-S120A, but not *pgm1Δ*, are dominant suppressors of sec53-V238M in the genetic assay (Figure 4C, 4D; Figure 4 — figure supplement 2). For the sec53-F126L background, we find no dominant suppressors.

**Reduction of Pgm1 activity alleviates deleterious effect of PMM2-CDG in yeast**
To determine how the evolved mutations alter Pgm1 enzymatic activity, we cloned mutant and wild-type PGM1 alleles into bacterial expression vectors, purified recombinant enzyme, and assayed phosphoglucomutase activity using a standard coupled enzymatic assay (Figure 5A; Figure 5 — figure supplement 1). We find that mutant Pgm1 have variable activities, ranging from near-wild type (Pgm1-T231A) to non-detectable (Pgm1-R64C and Pgm1-D295N) (Figure 5B, 5C). The near complete loss of activity of Pgm1-D295N is unsurprising since D295 coordinates a Mg²⁺ ion that plays an essential role during catalysis (Stiers et al., 2016) and we verify that all the active forms show very low activity in the presence of EDTA (Figure 5 — source data 1). Thermostability did not differ between enzymes with detectable activity (Figure 5 — figure supplement 2).

Comparison of the kinetic parameters of active mutant enzymes shows a reduction of maximal velocity (Vₘₐₓ) between 27%-72% relative to wild-type Pgm1. Based on the apparent Michaelis constant (Kₘ), substrate affinities of Pgm1-G514C and Pgm1-T521K are lower than wild-type Pgm1 (t=4.30 and 3.14, df=35.78 and 20.47, p=0.0001 and 0.0051, respectively, Welch’s modified t-test). Pgm1-T231A shows an increased affinity compared to wild-type Pgm1, but this difference is not statistically significant (t=1.94, df=34.68, p=0.0601, Welch’s). Together these indicate that the five evolved pgm1 mutations have varying effects on enzymatic activity.

The relationship between pgm1 fitness and Pgm1 Vₘₐₓ is best fit by a quadratic, rather than a linear, function (Figure 5D). Therefore, optimal fitness is attained by tuning down, but not eliminating, Pgm1 activity.

Mutant Pgm1 does not have increased phosphomannomutase activity

Phosphoglucomutases can exhibit low levels of phosphomannomutase activity, and we reasoned that active-site mutations in Pgm1 could alter epimer specificity from glucose to mannose, directly compensating for the loss of Sec53 activity (Lowry and Passonneau, 1969). We tested this in two ways. First, we directly measured phosphomannomutase activity of wild-type Pgm1 and two mutant Pgm1, using a ³¹P-NMR spectroscopy-based assay (Figure 5 — figure supplements 1, 3A). We find that wild-type Pgm1 and Pgm1-G514C show comparably low phosphomannomutase activity, accounting for 3.5% and 3.0% of their phosphoglucomutase activity, respectively. We could not detect any phosphomannomutase activity for Pgm1-D295N. We also tested for phosphomannomutase activity indirectly by determining whether mannose-1-phosphate (M1P) acted as a competitive inhibitor in the phosphoglucomutase assay. If mutant Pgm1 had altered epimer specificity, we would expect M1P to compete with glucose-1-phosphate for residency within the active site, leading to an apparent decrease in
phosphoglucomutase activity. However, we find no effect of the addition of M1P on phosphoglucomutase activity for any of the Pgm1 enzymes tested (Figure 5 — figure supplement 3B). Together, these results indicate that mutant Pgm1 does not have enhanced phosphomannomutase activity.

Pgm1 mutations increase intracellular G16P levels

Glucose-1,6-bisphosphate (G16P) is required as an activator of both Pgm1 and Pmm2 (Sec53) and can stabilize pathogenic variants of Pmm2 (Monticelli et al., 2019). The only known source of G16P in yeast is low-level dissociation during the phosphoglucomutase reaction of Pgm1 and Pgm2. We reasoned that evolved pgm1 mutations may increase intracellular levels of G16P which, in turn, would stabilize Sec53-V238M. Each active form of Pgm1 exhibits barely-detectable activity in the absence of G16P and we determined an apparent half maximal effective concentration (EC₅₀) of G16P for several Pgm1 enzymes (Figure 5 — source data 1). Given that Pgm1 is the minor isoform of phosphoglucomutase in yeast, we also reasoned that it could act as a glucose-1,6-bisphosphatase, similar to human PMM1 (Veiga-da-Cunha et al., 2008). We performed a specific glucose-1,6-bisphosphatase assay on wild-type and mutant Pgm1 enzyme (Figure 5 — figure supplement 1). However, none of the mutant Pgm1 enzymes have detectable glucose-1,6-bisphosphatase activity.

We next assessed G16P levels for two pgm1 mutant alleles in both the pACT1-sec53-V238M and the pACT1-SEC53-WT backgrounds (Figure 5 — figure supplement 4). We find that strains heterozygous for pgm1-T521K or pgm1-D295N show statistically significant increases in the amount of G16P present compared to wild-type PGM1, in the sec53-V238M background (W=24 and 8, p=0.003 and 0.0002, respectively, Mann–Whitney U test). However, this difference is not significant in the SEC53-WT background (W=41 and 15, p=0.35 and 0.078, respectively, Mann–Whitney).

Finally, we also reasoned that pgm1 mutations could differently affect the forward and reverse directions of the phosphoglucomutase reaction, with possible effects on the flux of metabolites within the cell. We analyzed the forward and reverse reactions of Pgm1, Pgm1-T231A and Pgm1-G514C using glucose-1-phosphate or glucose-6-phosphate (G1P or G6P) as the substrate (Figure 5 — figure supplement 1). We again used ³¹P-NMR spectroscopy, as G1P and G6P have clearly distinguishable signals (Figure 5 — figure supplement 5). The ratio of forward to reverse reactions are 3.0 ± 1.2 and 4.3 ± 1.1 (± standard deviation) for Pgm1-T231A and Pgm1-G514C, respectively. Although a slightly higher ratio was obtained for wild-type
Pgm1 (7.4 ± 3.1), the differences between wild-type and Pgm1-T231A or Pgm1-G514C are not statistically significant (\(W=1\) and 2, \(p=0.057\) and 0.53, respectively, Mann–Whitney).

**DISCUSSION**

The budding yeast *Saccharomyces cerevisiae* is a powerful system for studying conserved aspects of eukaryotic cell biology due to its fast doubling time, small genome size, genetic tractability, and the wealth of genomics tools available (Botstein and Fink, 2011). Many human genes are functionally identical to—and can complement—their yeast homologs (Kachroo et al., 2015). "Humanizing" yeast by replacing a yeast ortholog with the human gene or making an analogous human mutation in a yeast ortholog enables functional studies of human disease (Franssens et al., 2013; Laurent et al., 2016). For example, Mayfield et al. characterized the severity of 84 alleles of human CBS (Cystathionine-β-synthase) that are associated with homocystinuria, identifying those alleles where co-factor supplementation can restore high levels of enzymatic function (Mayfield et al., 2012). Gammie et al. characterized 54 MSH2 variants associated with hereditary nonpolyposis colorectal cancer (HNPCC) showing that about half of the variants have enzymatic function but are targeted for degradation (Gammie et al., 2007). Subsequent work showed that treatment with proteasome inhibitors restores mismatch repair and chemosensitivity in yeast harboring these disease-associated variants (Arlow et al., 2013). In additional to functional characterization, yeast models of human disease enable screens for genetic interactions, thereby uncovering new avenues for therapeutic intervention. Wiskott-Aldrich syndrome, for example, is due to mutations in WAS, the human homolog of LAS17. Using a temperature-sensitive lethal allele of *las17*, Filteau et al. isolated compensatory mutations in two yeast strains. The authors identified both common and background-specific mechanisms of compensation, including loss-of-function of *CNB1* (Calcineurin B), which is phenocopied by inhibition with cyclosporin A (Filteau et al., 2015).

Here we use experimental evolution to identify mechanisms of genetic compensation in humanized yeast models of PMM2-CDG. We evolved 96 replicate populations for 1,000 generation in rich glucose medium using strains carrying wild-type SEC53 (the yeast homolog of *PMM2*) and two human disease-associated alleles (*sec53*-V238M and *sec53*-F126L). We show that compensatory mutations arose throughout the evolution experiment. Fitness gains were greater for populations with the p*ACT1*-sec53-V238M allele compared to the p*ACT1*-sec53-F126L allele, which showed modest gains in fitness (Figure 1C). This indicates that the number of compensatory mutations and/or the ameliorative effects of compensatory mutations are greater for the p*ACT1*-sec53-V238M allele compared to the p*ACT1*-sec53-F126L allele. Our
sequencing and reconstruction experiments show that both explanations are true. While the pACT1-sec53-V238M populations showed several unique targets of selection, the pACT1-sec53-F126L populations mostly acquired mutations in targets of selection observed in other evolution experiments (Figure 2A). In addition, the genetic reconstruction experiments show that some of the pgm1 mutations are recessive suppressors of sec53-F126L, whereas all five pgm1 mutations are dominant suppressors of sec53-V238M (Figure 4). The latter is unsurprising given that each pgm1 mutation arose as a heterozygous mutation in a sec53-V238M autodiploid background.

Twenty-four genes have been associated with Type 1 CDG in humans (Aebi et al., 1999). All but two Type 1 CDG genes have at least one functional homolog in yeast, and most map one-to-one (Figure 2 — source data 3). We find an overrepresentation of mutations in Type 1 CDG homologs in the evolved pACT1-sec53-V238M populations (Figure 2B). This enrichment is striking considering that we observe a significant depletion of mutations in these same genes aggregated across evolution experiments with wild-type SEC53, which suggests that they are normally under purifying selection. Specifically, we find five mutations in PGM1, two in ALG9, and one in ALG12. In addition, one ALG7 mutation was identified in a single pACT1-sec53-F126L population. Of these four, only PGM1 is a known SEC53 genetic interactor, and none are known Sec53 physical interactors. ALG7 encodes an acetylglucosaminephosphotransferase responsible for the first step of lipid-linked oligosaccharide synthesis, downstream of SEC53 in the N-linked glycosylation pathway (Barnes et al., 1984; Kukuruzinska and Robbins, 1987). ALG9 and ALG12 act downstream of SEC53 and encode mannosyltransferases, responsible for transferring mannose residues from dolichol-phosphate-mannose to lipid-linked oligosaccharides (Burda et al., 1999, 1996; Cipollo and Trimble, 2002; Frank and Aebi, 2005). This oligosaccharide is eventually transferred to a polypeptide. Each of the evolved mutations in these genes are predicted to have deleterious effects on protein function based on PROVEAN scores (Supplementary File 1) (Choi and Chan, 2015). This suggests that prodding steps in N-linked glycosylation alleviates the deleterious effect of sec53 disease-associated alleles, perhaps by altering pathway flux to match lowered mannose-1-phosphate availability. Evidence from human studies supports the idea of downstream genetic modifiers affecting PMM2-CDG phenotypes. For example, there is not a direct correlation between clinical phenotypes and biochemical properties of PMM2 (Citro et al., 2018; Freeze and Westphal, 2001). One such modifier is a variant of the glucosyltransferase ALG6, which has been implicated in worsening clinical outcomes of PMM2-CDG individuals (Bortot et al., 2013; Westphal et al., 2002).
In addition to Type 1 CDG homologs, we identify several other classes of putative genetic suppressors. Both the sec53-V238M and sec53-F126L mutations retain partial functionality and Lao et al., 2019 showed that increasing expression of these alleles improves growth. We, therefore, expected to find copy number variants (CNVs) and aneuploidies as compensatory mutations. Though we do identify several strains that show evidence of CNVs at the HO locus on Chromosome IV, where the sec53 alleles reside in our strains, karyotype changes are not a major route of adaptation (Figure 2 — source data 1). Reduced function of mutant Sec53 could be due to destabilization and degradation of the protein. We identify recurrent mutations in the 26S proteasome lid subunit RPN5 in the pACT1-sec53-V238M background, in the E3 ubiquitin ligase UBR1 in the pACT1-sec53-F126L background, and in the ubiquitin-specific protease UBP3 in both pACT1-sec53 backgrounds (Figure 2). In addition, we identify a mutation in the ubiquitin-specific protease UBP15 in a single pACT1-sec53-V238M clone. And finally, we observe multiple independent mutations in the known SEC53-interactors RPN5, SRP1, and YNL011C in sec53 populations, which could have positive genetic interactions with sec53 (Figure 2).

We find a high probability that the mutational spectrum of PGM1 (5 missense mutations, 0 frameshift/nonsense) resembles selection for non-loss-of-function (posterior probability = 0.96). However, PGM1 loss-of-function (pgm1Δ) provides a fitness benefit indistinguishable from two evolved mutations (pgm1-R64C and pgm1-D295N) and higher than one evolved mutation (pgm1-T231A). Likewise, the pgm1Δ allele restores invertase and carboxypeptidase Y glycosylation and growth in the tetrad analyses, albeit recessively. It is not immediately clear, therefore, why we do not observe frameshift/nonsense mutations in PGM1 in the evolution experiment. We have previously shown that genetic interactions between evolved mutations are not always recapitulated by gene deletion (Vignogna et al., 2021). Given that most of the evolved clones containing pgm1 mutations are more fit than the reconstructed strains, it is possible that other evolved mutations interact epistatically only with non-loss-of-function pgm1 mutations. However, there are no shared mutational targets (genes or pathways) among the evolved clones with pgm1 mutations and only one evolved pgm1 clone contains a mutation in a known PGM1 interactor (FRA1). These suggest any putative genetic interactions with our evolved pgm1 mutations are allele-specific.

Using tetrad dissections, we show that each evolved pgm1 mutation and the catalytically-dead pgm1-S120A mutation are dominant suppressors of sec53-V238M. pgm1Δ is not a dominant suppressor based on the tetrad analyses, contrary to the fitness assays where the heterozygous pgm1Δ allele confers a fitness benefit comparable to several evolved
mutations. This discrepancy likely results from differences in ploidy or growth medium of the two experiments — diploids in liquid culture versus haploids on agar plates. We also find that several pgm1 mutations (T521K, D295N, pgm1Δ, S120A) are recessive suppressors of the sec53-F126L allele in the tetrad dissections, whereas we were unable to detect any improvement using fitness assays. Three of these four mutations have no detectable enzymatic activity. However, the R64C allele, which also does not have detectable enzymatic activity does not suppress.

To test specific hypotheses for the mechanism of suppression of sec53 disease alleles by mutation of pgm1, we characterized the biochemical properties of purified recombinant Pgm1 mutant proteins. We find that phosphoglucomutase activity ranges from no-detectable activity (R64C and D295N) to near wild-type (T231). Based on well-characterized human and rabbit PGM1 structures, R64C and D295N mutations likely affect active-site integrity (Liu et al., 1997; Stiers et al., 2016). R64 helps hold the catalytic serine (S120) in place and D295 coordinates a catalytically-essential Mg$^{2+}$ ion. The T231A mutation, which occurs in a residue near the metal binding loop, shows the highest activity levels among our mutant Pgm1 enzymes. The other two mutations with low but detectable activity, G514C and T521K, both occur in the phosphate-binding domain of Pgm1, a region important for substrate binding (Beamer, 2015; Stiers et al., 2017a, 2017b; Stiers and Beamer, 2018). Comparing pgm1 fitness effects versus their corresponding enzyme $V_{\text{max}}$ we find an inverted U-shaped curve, where reducing phosphoglucomutase activity improves fitness, but complete loss of activity overshoots the optimum (Figure 5D). Plotting fitness versus $k_{\text{cat}}/K_{\text{m}}$ results in a qualitatively similar trend, although comparing $k_{\text{cat}}/K_{\text{m}}$ between mutant enzymes may not be appropriate (Eisenthal et al., 2007).

We tested several hypotheses involving Pgm1 alteration-of-function. First, the evolved Pgm1 proteins could directly complement the loss of Sec53 phosphomannomutase activity by switching epimer specificity from glucose to mannose. However, we do not observe increased phosphomannomutase activity in the Pgm1 mutant proteins, nor is this hypothesis consistent with our genetic data: direct complementation would be expected to suppress both the sec53-V238M and sec53-F126L alleles.

A second possible mechanism of suppression is increasing the production of glucose-1,6-bisphosphate (G16P). G16P is an endogenous activator and stabilizer of Pmm2 (Sec53). Compounds that raise G16P levels by increasing its production and/or slowing its degradation show promise as candidates for treatment of PMM2-CDG (Iyer et al., 2019; Monticelli et al., 2019). Whereas higher eukaryotes and some bacteria have a dedicated glucose-1,6-
bisphosphate synthase, in yeast G16P is produced as a dissociated intermediate of the phosphoglucomutase reaction (Maliekal et al., 2007; Neumann et al., 2021). We hypothesized that evolved mutations in PGM1 may increase the rate of G16P dissociation. Recent work has shown that a mutation affecting Mg$^{2+}$ coordination in L. lactis β-phosphoglucomutase can increase dissociation of β-G16P \textit{in vitro} (Wood et al., 2021). While we did not directly measure G16P synthase activity of Pgm1, we find that intracellular levels of G16P are increased in strains with \textit{pgm1}-T521K or \textit{pgm1}-D295N. We cannot, however, determine if the observed increase in G16P is sufficient to rescue glycosylation. There may be other metabolic changes caused by the \textit{pgm1} mutations that impact Sec53 activity and glycosylation.

A third possible mechanism of compensation is the indirect increase of G16P by increasing the relative flux of the reverse (G6P to G1P) reaction relative to the forward (G1P to G6P) reaction. This would create a futile cycle of G1P/G6P interconversion, which is expected to result in higher intracellular G16P. This hypothesis is attractive in that it accounts for three observations regarding the evolved \textit{pgm1} mutations: (1) the observation of only missense (not nonsense or frameshift) mutations in the evolution experiment, (2) the dominance of suppressors in our genetic assay, and (3) greater extent of suppression for the stability mutant (V238M) of \textit{SEC53}. Nevertheless, the observation that complete loss of Pgm1 enzymatic activity improves growth of \textit{sec53} mutants suggests that there are multiple mechanisms of suppression through \textit{PGM1}.

There is truth to the saying that “a selection is worth a thousand screens.” Experimental evolution takes what would otherwise be a screen—looking for larger colonies on a field of smaller ones—and turns it into a selection. Here we demonstrate the power of yeast experimental evolution to identify genetic mechanisms that compensate for the molecular defects of PMM2-CDG disease-associated alleles. This general approach is applicable to other human disease alleles that affect core and conserved biological processes including protein glycosylation, ribosome maturation, mitochondrial function, and RNA modification. Mutations that impinge upon these processes are often highly pleiotropic. In humans, salient phenotypes may be neurological or developmental, but in yeast, these disease alleles invariably lead to slow growth. With a population size of $10^5$, evolution can act on differences as small as 0.001%, far below the ability to resolve on plates. Even our best fluorescence-based assays can only resolve differences of $\sim 0.1\%$ (Lang and Botstein, 2011). With a genome size of $10^7$ bp, a mutation rate of $10^{-10}$ per bp per generation, and with continuous selective pressure exerted over thousands of generations, each population will sample hundreds of thousands of coding-sequence mutations. Over longer time-scales, experimental evolution can be used to identify
rare suppressor mutations, suppressor mutations with modest fitness effects, and/or complex compensatory interactions involving multiple mutations, which are largely absent from current genetic interaction networks.
<table>
<thead>
<tr>
<th>Reagent type (species) or resource</th>
<th>Designation</th>
<th>Source or reference</th>
<th>Identifiers</th>
<th>Additional information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recombinant DNA reagent</td>
<td>pML104-NatMx3</td>
<td>Adgene (83477)</td>
<td>Cas9 plasmid</td>
<td>modified plasmids available upon request</td>
</tr>
<tr>
<td>Recombinant DNA reagent</td>
<td>pAG25</td>
<td>Addgene (35121)</td>
<td>integrating plasmid</td>
<td>modified plasmids available upon request</td>
</tr>
<tr>
<td>Recombinant DNA reagent</td>
<td>pGEX-2T</td>
<td>Cytiva Life Sciences (28954653)</td>
<td>bacterial expression plasmid</td>
<td>modified plasmids available upon request</td>
</tr>
<tr>
<td>Antibody</td>
<td>anti-carboxypeptidase rabbit polyclonal antibody</td>
<td>Abcam (ab181691)</td>
<td>(1:1000)</td>
<td></td>
</tr>
<tr>
<td>Antibody</td>
<td>anti-rabbit IgG HRP-conjugated mouse monoclonal antibody</td>
<td>Cell Signaling Technologies (5127)</td>
<td>(1:2000)</td>
<td></td>
</tr>
<tr>
<td>Antibody</td>
<td>anti-invertase goat polyclonal antibody</td>
<td>Novus Biologicals (NB120-20597)</td>
<td>(1:1000)</td>
<td></td>
</tr>
</tbody>
</table>
Experimental Evolution

The haploid strains used in the evolution experiment are S288c derivatives and were described previously (Lao et al., 2019). Each strain maintains a URA3-marked plasmid encoding wild-type SEC53 (pTC416-SEC53 described in Lao et al. 2019). Strains with the pSEC53-sec53-F126L allele grew too slowly to keep up with a 1:2\(^{10}\) dilution every 24 hours.

To initiate the evolution experiment, strains were struck to synthetic defined (SD) media (CSM minus arginine, 0.67% yeast nitrogen base, 2% dextrose) containing 5-Fluoroorotic Acid (5FOA) (Zymo Research, Irvine, CA, USA) to isolate cells that spontaneously lost pTC416-SEC53. A single colony was chosen for each strain and used to inoculate 10 mL of YPD (1% yeast extract, 2% peptone, 2% dextrose) plus ampicillin and tetracycline. These cultures grew to saturation then were distributed into 96-well plates. Every 24 hours populations were diluted 1:2\(^{10}\) using a BiomekFX liquid handler into 125 μL of YPD plus 100 μg/mL ampicillin and 25 μg/mL tetracycline to prevent bacterial contamination. Plates were then left at 30°C without shaking. The dilution scheme equates to 10 generations of growth per day at an effective population size of ~10\(^5\). Every 100 generations, 50 μL of 60% glycerol was added to each population and archived at -80°C.

\(OD_{600}\) was measured every 50 generations over the course of the evolution experiment. After daily dilutions were completed, populations were resuspended by orbital vortexing at 1050 rpm for 15 seconds then transferred to a Tecan Infinite M200 Pro plate reader for sampling.

Whole-Genome Sequencing

Benomyl assays were performed by spotting 5 μL of populations onto YPD plus 20 μg/mL benomyl (dissolved in DMSO) and incubating at 25°C. Ploidy was then inferred by visually comparing growth of evolved populations to control haploid and diploid strains.

Single clones were isolated for sequencing by streaking 5 μL of cryo-archived populations to YPD agar. One clone from each population was randomly chosen and grown to saturation in 5 mL YPD, pelleted, and frozen at -20°C. Genomic DNA was harvested from frozen cell pellets using phenol-chloroform extraction and precipitated in ethanol. Total genomic DNA was used in a Nextera library preparation as described previously (Buskirk et al., 2017).
Pooled clones were sequenced using an Illumina NovaSeq 6000 sequencer by the Sequencing Core Facility at the Lewis-Sigler Institute for Integrative Genomics at Princeton University.

**Sequencing Analysis**

Raw sequencing data were concatenated and then demultiplexed using a dual-index barcode splitter (bitbucket.org/princeton_genomics/barcode_splitter/src). Adapter sequences were trimmed using Trimmomatic (Bolger et al., 2014). Modified S288c reference genomes were constructed using reform (github.com/gencorefacility/reform) to correct for strain-construction-related differences between our strains and canonical S288c. Trimmed reads were aligned to these modified S288c reference genomes using BWA and mutations were called using FreeBayes (Garrison and Marth, 2012; Li and Durbin, 2009). VCF files were annotated with SnpEff (Cingolani et al., 2012). All calls were confirmed manually by viewing BAM files in IGV (Thorvaldsdóttir et al., 2013). Clones were predicted to be diploids if two or more mutations were called at an allele frequency of 0.5. Copy number variants (CNVs) and aneuploidies were called via changes in sequencing coverage using Control-FREEC (Boeva et al., 2012). CNVs and aneuploidies were confirmed by visually inspecting coverage plots.

**Yeast Strain Construction**

Evolved mutations were reconstructed via CRISPR/Cas9 allele swaps. For mutations that fall within a Cas9 gRNA site (alg9-S230R, pgm1-T231A, pgm1-G514C), repair templates were produced by PCR-amplifying 500-2000bp fragments centered around the mutation of interest from evolved clones. Commercially-synthesized dsDNA fragments (Integrated DNA Technologies, Coralville, IA, USA) were used as repair templates for all other mutations (pgm1-R64C, pgm1-S120A, pgm1-D295N, pgm1-T521K, pgm1Δ). These 500bp fragments contained our mutation of interest as well as 1-2 synonymous mutations in the Cas9 gRNA site to halt cutting. The pgm1Δ repair template was a dsDNA fragment consisting of 250bp upstream then 250bp downstream of the ORF. Repair templates were co-transformed into haploid ancestral strains with a plasmid encoding Cas9 and gRNAs targeting near the mutation site (Addgene #83476) (Laughery et al., 2015).

Heterozygous mutant strains were constructed by mating haploid mutants to MATα versions of their respective ancestral strains. Homozygous mutant strains were constructed by reconstructing mutations in MATα versions of the ancestral strains and mating them to the respective MATα mutant strain. Successful genetic reconstructions were confirmed via Sanger sequencing (Psomagen, Rockville, MD, USA).

Linked PGM1 strains used for tetrad dissections were constructed by transforming strains with a linearized integrating plasmid (Addgene #35121) containing wild-type PGM1
Successful integration of the plasmid next to the endogenous \textit{PGM1} locus was confirmed via PCR. Strain information in Supplementary File 2.

**Competitive Fitness Assays**

We measured the fitness effect of evolved mutations using competitive fitness assays described previously with some modifications (Buskirk et al., 2017). Query strains were mixed 1:1 with a fluorescently labeled version of the p\textit{ACT1}-\textit{SEC53}-WT ancestral diploid strain. Each p\textit{ACT1}-sec53-F126L strain was outcompeted immediately by the reference at this ratio, so we also tried mixing at a ratio of 50:1. Cocultures were propagated in 96-well plates in the same conditions in which they evolved for up to 50 generations. Saturated cultures were sampled for flow-cytometry every 10 generations. Each genotype assayed was done so with at least 24 technical replicates (competitions) of 4 biological replicates (2 clones isolated each from 2 isogenic but separately-constructed strains). Analyses were performed in Flowjo and R.

**LOF/non-LOF Bayesian Analysis**

From reconstruction data from previously published evolution experiments (Fisher et al., 2018; Lang et al., 2013; Marad et al., 2018) we identified ten genes where selection is acting on loss-of-function (LOF: \textit{ACE2}, \textit{CTS1}, \textit{ROT2}, \textit{YUR1}, \textit{STE11}, \textit{STE12}, \textit{STE4}\textsubscript{haploids}, \textit{STE5}, \textit{IRA1}, and \textit{IRA2}) and six genes where selection is for non-loss-of-function (non-LOF: \textit{CNE1}, \textit{GAS1}, \textit{KEG1}, \textit{KRE5}, \textit{KRE6}, and \textit{STE4}\textsubscript{autodiploids}). These data established prior probabilities that selection is acting on LOF (0.625) or non-LOF (0.375). We then determined the conditional probabilities of missense and frameshift/nonsense mutations given selection for LOF and non-LOF using 240 mutations across these 16 genes as well as 414 5FOA-resistant mutations at \textit{URA3} and 454 canavanine-resistant mutations at \textit{CAN1} (Lang and Murray, 2008). From these data we can estimate the log likelihood and posterior probabilities that selection is acting on LOF or non-LOF given the observed mutational spectrum for any given gene (Supplementary File 3).

**CPY and Invertase Blots**

Strains were grown in 5mL YPD plus 100 \(\mu\)g/mL ampicillin and 25 \(\mu\)g/mL tetracycline until saturated, then pelleted, and frozen at -20°C. Cell pellets were lysed in Ripa lysis buffer (150mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 25mM Tris (pH 7.4)) with protease inhibitors (Thermo Fisher Scientific, Waltham, MA, USA) and 10mM DTT, incubated for 30 min on ice, sonicated 5 times briefly, incubated for a further 10 min on ice, and centrifuged at 20,000xg for 10 min at 4°C. Supernatant was quantified by Micro BCA Protein Assay (Thermo Fisher). 30 \(\mu\)g of each lysate were prepared in Lamelli buffer and were incubated at 95°C for 5 min and chilled at 4°C. Lysates were separated on a 6% or 8% SDS gel.
PAGE gel. Protein was transferred to 0.2 µm pore nitrocellulose at 100 volts for 100 min at 4°C in Towbin buffer. The membrane was rinsed and stained with Ponceau S for normalization. The membranes were blocked with 5% milk/TBST for 1 hour at room temperature. Carboxypeptidase Y blots were incubated with an anti-carboxypeptidase antibody at 1:1000 overnight at 4°C and washed 3 times with TBST. The blots were then incubated with anti-rabbit IgG HRP diluted 1:2000 in milk/TBST for 1 hour, washed 3 times and developed with ECL reagent (Bio-Rad Laboratories, Hercules, CA, USA). Invertase blots were prepared similarly with an anti-invertase antibody and anti-goat IgG HRP. All images were captured on the Bio-Rad ChemiDoc MP Imaging System (Bio-Rad). Analysis was done with Image Lab Software (Bio-Rad). Raw images of blots and Ponceau stain controls are available in Figure 3 source data.

**Tetrad Dissection and Inference of Genetic Interactions**

Heterozygous yeast strains (i.e., SEC53/sec53 PGM1/pgm1) were sporulated by resuspending 1 ml of overnight YPD culture in 2 ml of SPO++ (1.5% potassium acetate, 0.25% yeast extract, 0.25% dextrose, 0.002% histidine, 0.002% tryptophan) and incubated on a roller-drum for ~7 days at room temperature. 10 tetrads per strain were dissected on YPD agar and then incubated for 48 hours at 30°C. We performed a log-likelihood test to determine if patterns of segregation are indicative of suppression (Figure 4 — source data 1). Note that in order to calculate conditional probabilities we had to include an error term (0.01) to account for biological noise in the real data. Our inference of suppression, however, is robust to our choice of error value.

**Bacterial Growth and Lysis**

Wild-type and mutant PGM1 alleles were cloned into the expression vector pGEX-2T. Cloned vectors were transformed into E. coli BL21(DE3). Bacteria were grown in lysogeny broth (LB) medium plus 0.1 mg/ml ampicillin. Each PGM1 allele was expressed by induction at 0.1 OD with 0.1 mg/mL IPTG for 16 hours at 15°C. Bacteria were harvested by centrifugation, washed with PBS, and stored at -80°C. Bacterial lysis was accomplished in 25 mM Tris buffer (pH 8) containing 1 mM EDTA, 2 mM DTT, 5% glycerol and 0.1 mM PMSF, by adding 1 mg/mL lysozyme and 2.5 µg/mL DNase. Clear extract was then obtained by centrifugation.

**Protein Purification**

Protein purification was accomplished using Glutathione Sepharose High Performance resin (GSTrap by Cytiva, Marlborough, MA, USA) and Benzamidine Sepharose 4 Fast Flow resin (HiTrap Benzamidine FF by Cytiva). Cleavage of the GST-tag was conducted on-column by adding thrombin. All the procedures were performed according to manufacturer’s
instructions. Briefly, clear extract obtained from 50 mL of bacterial culture was loaded onto the GSTrap column (5mL), previously equilibrated with 25 mM Tris (pH 8) containing 2 mM DTT and 5% glycerol. Unbound protein was eluted, then the column was washed with 20 mM Tris (pH 8) containing 1 mM DTT, 150 mM NaCl, 1 mM MgCl₂, and 5% glycerol (buffer A). Thrombin (30 units in 5 mL of buffer A) was loaded and the column was incubated for 14-16 hours at 10°C. GSTrap and HiTrap Benzamidine columns were connected in series, and elution of the untagged protein was accomplished with buffer A. Fractions were analyzed by SDS-PAGE and activity assays. Active fractions were finally collected and concentrated by ultrafiltration. A yield spanning 1.0-4.6 mg of protein per liter of bacterial culture was obtained.

Each protein was obtained in a pure, monomeric form as judged by SDS-PAGE and gel filtration analyses, with a single band observed at the expected molecular weight (63 kDa). Gel filtration analysis was performed on BioSep-SEC-S 3000 column (Phenomenex, Torrance, CA, USA) at 1 mL/min. The eluent was 20 mM Tris (pH 8), 1 mM MgCl₂, 150 mM NaCl.

Activity Assays

Phosphoglucomutase activity was assayed spectrophotometrically at 340 nm and 29°C by following the reduction of NADP⁺ to NADPH in a 0.3 mL reaction mixture containing 25 mM Tris (pH 8), 5 mM MgCl₂, 1 mM DTT, 0.25 mM NADP⁺, and 2.7 U/mL glucose 6-phosphate dehydrogenase in the presence of 0.3 mM glucose-1-phosphate (G1P) and 0.02 mM glucose-1,6-bisphosphate (G16P). Additional experiments were performed with the addition of mannose-1-phosphate (M1P; 10, 50, 200 μM). Kᵅ were evaluated by measuring activity in the presence of G1P ranging from 0 mM to 0.6 mM. Analyses were performed in R using the drc package (Ritz et al., 2015). Bisphosphatase activity was measured spectrophotometrically at 340 nm and 29°C in the presence of 0.1 mM G16P, 0.25 mM NADP⁺, and 2.7 U/mL glucose 6 phosphate dehydrogenase. Activity expressed as the number of micromoles of substrate transformed per minute per mg of protein under the standard conditions.

Thermostabilities of Pgm1 were determined by incubating purified protein for 5 or 10 minutes at different temperatures (30, 35, 40, 45 °C) in 20 mM Tris (pH 8), 1 mM MgCl₂, 150 mM NaCl, 5% glycerol, and 0.1 mg/mL BSA. After cooling on ice, residual activity was measured under standard conditions.

³¹P-NMR Spectroscopy

Phosphoglucomutase and phosphomannomutase activity were measured by ³¹P-NMR spectroscopy (Citro et al., 2017). This assay allows us to exclude the effects on the change in absorbance due to impurities that could be substrates for the ancillary enzymes required for the assay. This is of utmost importance when the activity is particularly low and measuring the rate
of change in absorbance requires long incubation times, as it is the case of phosphomannomutase activity for Pgm1. A discontinuous assay was performed. Appropriate amounts of proteins were incubated at 30°C with 1 mM G1P or M1P in 20 mM Tris (pH 8), 1 mM MgCl₂, 0.1 mg/ml BSA, in the presence of 20 μM G16P for up to 60 min. The reaction was stopped with 50 mM EDTA on ice and heat inactivation. The content of the residual substrate (M1P or G1P) and/or the product (M6P or G6P) were measured recording ³¹P-NMR spectra. Creatine phosphate was added as an internal standard for the quantitative analysis. The ¹H-decoupled, one-dimensional ³¹P spectra were recorded at 161.976 MHz on a Bruker Avance III HD spectrometer 400MHz, equipped with a BBO BB-H&F-D CryoProbe Prodigy fitted with a gradient along the Z-axis, at a probe temperature of 27°C. Spectral width 120 ppm, delay time 1.2s, pulse width of 12.0μs were applied. All the samples contained 10% ²H₂O for internal lock.

Similarly, forward (G1P to G6P) and reverse (G6P to G1P) phosphoglucomutase activities were measured following the same procedure described above, with 1mM G1P or G6P as the substrate.

Quantification of Glucose-1,6-Bisphosphate Abundance

Yeast metabolite extraction was performed as described previously (Gonzalez et al., 1997). Briefly, five replicate cultures per genotype were grown in 5mL YPD plus 100 μg/mL ampicillin and 25 μg/mL tetracycline at 30°C. 10⁷ cells of mid-log culture were collected on nylon filters, washed with 10 mL cold PBS, frozen in liquid nitrogen, and lyophilized. Cells were then treated with an ice-cold solution containing 14% HClO₄ and 91 mM imidazole, frozen and thawed five times (dry ice/acetone followed by 40°C bath) with vigorous shaking between each cycle, then centrifuged at 13500 x g at 4°C. Supernatant was neutralized with 3M K₂CO₃ and centrifuged again at 13500 x g at 4°C to eliminate salt precipitate.

G16P in the metabolite extracts was measured through stimulation of rabbit muscle phosphoglucomutase as described previously (Veiga-da-Cunha et al., 2008). Phosphoglucomutase activity was assayed spectrophotometrically at 340 nm, in a mixture containing 87 mM Tris (pH 7.6), 5.6 mM MgCl₂, 0.11 mM EGTA, 0.1 mg/mL BSA, 0.048 mM NADP⁺, 0.48 mM G1P, 0.26 U/mL glucose 6-phosphate dehydrogenase, at 36°C. G1P had previously been purified from G16P through anionic exchange chromatography on AG1x8 Hydroxide Form column in step gradient of triethylammonium bicarbonate from 0.01 M to 1 M (Monticelli et al., 2019). Three technical replicates for each of the five biological replicates were assayed. 0.0-0.15 μM commercial G16P (Merck & Co., Rahway, NJ, USA) was used as the standard.
DATA AVAILABILITY
The short-read sequencing data reported in this study have been deposited to the NCBI BioProject database, accession number PRJNA784975.

The following previously published datasets were used:
Lang et al., 2013: NCBI BioProject PRJNA205542
Fisher et al., 2018: NCBI BioProject PRJNA422100
Johnson et al., 2021: NCBI BioProject PRJNA668346

ACKNOWLEDGEMENTS AND FUNDING
We thank members of the Andreotti Lab and members of the Lang Lab for comments on the manuscript. We thank M. Kathryn Iovine for sharing the pGEX-2T plasmid. We thank Lesa Beamer for useful discussions. This study was supported by the National Institutes of Health: R01GM127420 to GIL and P20GM139769 to RS (Trudy Mackay PI/PD). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This study was also supported by DiSTABiF, University of Campania “Luigi Vanvitelli” (fellowship POR Campania FSE 2014/2020 “Dottorati di Ricerca Con Caratterizzazione Industriale” to MA). Portions of this research were conducted on Lehigh University’s Research Computing infrastructure partially supported by the National Science Foundation (Award 2019035). Perlara PBC provided funding support for reagents and personnel time.

COMPETING INTERESTS
EOP is CEO of Maggie’s Pearl, LLC and CEO of Perlara PBC. He holds an ownership stake in both companies.
REFERENCES

Bjurssel C, Uller A, Wahlström JG, Briones P, Cardo E, Clayton P, Winchester B,
Cormier-Dale V, de Lonlay P, Cuer M, Dupré T, Seta N, de Koning T, Dorland L, de
Loos F, Kupers L, Fabritz L, Hasilik M, Marquardt T, Niehues R, Freeze H, Grünewald S,
Heykants L, Jaeken J, Matthijs G, Schollen E, xKeir GK, Kjaergaard S, Schwartz M,
Krasnewich D, Lehle L, Peters V, Raab M, Saether O, Schachter H, Van Schaftingen E,
glycoprotein syndromes become congenital disorders of glycosylation: An updated

Andreotti G, Monti MC, Citro V, Cubellis MV. 2015. Heterodimerization of Two Pathological
Mutants Enhances the Activity of Human Phosphomannomutase2. *PLOS ONE* **10**:
ed0139882. doi:10.1371/journal.pone.0139882

significant unstable variants of the mismatch repair protein Msh2. *Proc Natl Acad Sci U

Saccharomyces cerevisiae: genetic analysis of an early step. *Molecular and Cellular

Beamer LJ. 2015. Mutations in hereditary phosphoglucomutase 1 deficiency map to key regions
of enzyme structure and function. *Journal of Inherited Metabolic Disease* **38**:243–256.
doi:10.1007/s10545-014-9757-9

Bevan P, Douglas HC. 1969. Genetic Control of Phosphoglucomutase Variants in

Boeva V, Popova T, Bleakley K, Chiche P, Cappo J, Schleiermacher G, Janoueix-Lerosey I,
Delattre O, Barillot E. 2012. Control-FREEC: a tool for assessing copy number and
doi:10.1093/bioinformatics/btr670

Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for Illumina sequence

Bortot B, Cosentini D, Faletra F, Biffi S, De Martino E, CarroZZi M, Severini GM. 2013. PMM2-

**189**:695–704. doi:10.1534/genetics.111.130765

Briso-Montiano A, Del Caño-Ochoa F, Vilas A, Velázquez-Campoy A, Rubio V, Pérez B,
Ramón-Maiques S. 2022. Insight on molecular pathogenesis and pharmacochaperoning
potential in phosphomannomutase 2 deficiency, provided by novel human
doi:10.1002/jimid.12461

the lipid-linked oligosaccharide in the endoplasmic reticulum of Saccharomyces
cerevisiae: identification of the ALG9 gene encoding a putative mannosyl transferase.

asymmetrically branched lipid-linked oligosaccharide in the endoplasmic reticulum is
ensured by the substrate specificity of the individual glycosyltransferases. *Glycobiology*
**9**:617–625. doi:10.1093/glycob/9.6.617


Cipollo JF, Trimble RB. 2002. The Saccharomyces cerevisiae alg12delta mutant reveals a role for the middle-arm alpha1,2Man- and upper-arm alpha1,2Manalpha1,6Man- residues of Glc3Man9GlcNAc2-PP-Dol in regulating glycoprotein glycan processing in the endoplasmic reticulum and Golgi apparatus. *Glycobiology* **12**:749–762. doi:10.1093/glycob/cwf082


Disorder of Glycosylation Type IL. The American Journal of Human Genetics 75:146–150. doi:10.1086/422367


Figures Legends

Figure 1. Experimental evolution of yeast models of congenital disorders of glycosylation. (A) Table of the various sec53 alleles used in this study. In vitro enzymatic activities of Pmm2 are relative to wild-type Pmm2 and were previously reported (Pirard et al., 1999). Relative growth rates of yeast carrying various SEC53 alleles were previously reported (Lao et al., 2019). (B) Diagram of the evolution experiment. Yeast carrying sec53 mutations implicated in human disease were used to initiate replicate populations in 96-well plates: 96 populations of each mutant genotype and 48 populations of each wild-type genotype. Populations were propagated in rich glucose media, unshaken, for 1,000 generations. (C) Single time-point OD$_{600}$ readings of populations were taken every 50 generations during the evolution experiment as a measure of growth rate. Each line represents one population.

Figure 1 — figure supplement 1. OD$_{600}$ readings of each population. Single time-point OD$_{600}$ readings of populations over the course of the evolution experiment. Every 50 generations, following daily transfer, populations were resuspended and OD was measured. Each line represents one population.

Figure 2. Mutations in Type 1 CDG homologs are enriched in sec53-V238M populations. (A) Heatmap showing number of nonsynonymous mutations per gene that arose in the evolution experiment. Genes with 2 or more unique nonsynonymous mutations (and each Type 1 CDG homolog with at least 1 mutation) are shown. pSEC53-SEC53-WT and pACT1-SEC53-WT are grouped as “SEC53-WT”. For comparison we show data from previously reported evolution experiments where the experimental conditions were identical to the conditions used here, aside from strain background and experiment duration (bottom 3 rows). Commonly mutated pathways are grouped for clarity. Asterisks (*) indicate previously known SEC53 genetic interactors (Costanzo et al., 2016; Kuzmin et al., 2018). (B) Binomial test for enrichment or depletion of mutations in Type 1 CDG homologs based on the number of nonsynonymous mutations observed in each experiment, the total number of yeast genes (5,906), and the number of genes that are Type 1 CDG homologs (24). “Combined WT” includes the SEC53-WT populations as well as three additional datasets: Lang et al. (2013), Fisher et al. (2018), Johnson et al. (2021).

Figure 2 — source data 1. Table of recurrent CNVs and aneuploidies in the evolution experiment.

Figure 2 — source data 2. Coverage plots of evolved clones.

Figure 2 — source data 3. Table of mutations in Type 1 CDG homologs.

Figure 2 — figure supplement 1. Number of de novo mutations per SEC53 genotype. Each circle represents the number of SNPs and small indels present in a sequenced clone (Supplementary File 1). pSEC53-SEC53-WT and pACT1-SEC53-WT are grouped as “SEC53-WT”. Distribution of points are shown as violin plots. Only statistically significant differences shown with bars. pACT1-sec53-V238M vs. SEC53-WT (p=0.326), pACT1-sec53-V238M vs. pACT1-sec53-F126L (p>0.0001), pACT1-sec53-F126L vs. SEC53-WT (p=0.0234) (df=167, F=9.67, one-way ANOVA with Tukey post-hoc test).
Figure 3. Evolved mutations rescue fitness and protein glycosylation defects of pACT1-sec53-V238M. (A) Average fitness effects and standard deviations of reconstructed heterozygous pgm1 mutations. Fitness effects were determined by competitive fitness assays against a fluorescently-labeled version of the diploid pACT1-SEC53-WT ancestor. Replicate measurements are plotted as gray circles. Pairs of pgm1 fitness effects with non-statistically-significant differences: R64C-D295N, R64C-pgm1Δ, R64C-S120A, D295N-pgm1Δ, G514C-T521K, G514C-S120A, and pgm1Δ-S120A (df=194, F=208.1, each p>0.05, one-way ANOVA with Tukey post hoc test). (B) Western blots of invertase (left) and carboxypeptidase Y (right) from ancestral and reconstructed strains. In panels A and B, plus signs (+) indicate wild-type alleles. Genotypes are either homozygous wild-type (+/+), homozygous mutant (mutation/mutation), or heterozygous (mutation/+).

Figure 3 — source data 1. Raw images of blots and Ponceau stains.

Figure 3 — figure supplement 1. Fitness effects of reconstructed mutations and evolved clones containing those same mutations. Average fitness effects and standard deviations of reconstructed heterozygous pgm1 and alg9 mutations (closed circles) compared to evolved clones containing those mutations plus 3-9 additional mutations (open circles). Replicate measurements are plotted as gray circles. Note there are two clones from different populations with an alg9-S230R mutation. Asterisks (*) represent statically significant differences between fitness effects of evolved clones and fitness effects of reconstructed clones (Welch’s modified t-test): pgm1-T231A (p<0.0001, t=36.1, df=28.9); pgm1-G514C (p<0.0001, t=11.8, df=18.4); pgm1-T521K (p<0.0001, t=33.8, df=27.3); pgm1-R64C (p<0.0001, t=52.9, df=24.3); pgm1-D295N (p=0.05, t=2.10, df=19.9); alg9-S230R (left) (p<0.0001, t=53.7, df=49.7); alg9-S230R (right) (p<0.0001, t=44.1, df=46.1).

Figure 3 — figure supplement 2. Fitness effects of pgm1 mutations in the SEC53-WT background. Average fitness effects and standard deviations of reconstructed pgm1 mutations in the diploid pACT1-SEC53-WT background. Replicate measurements are plotted as gray circles. Plus signs (+) indicate wild-type alleles.

Figure 3 — figure supplement 3. Fitness effects of homozygous pgm1 mutations. Average fitness effects and standard deviations of reconstructed pgm1 mutations in the diploid pACT1-sec53-V238M background as heterozygous (mutation/+) or homozygous (mutation/mutation) alleles. Replicate measurements are plotted as gray circles. Comparison of heterozygous and homozygous allele fitness effects (Welch’s modified t-test): pgm1-T231A (p=0.002, t=3.35, df=38.6); pgm1-G514C (p=0.008, t=2.85, df=27.8); pgm1-T521K (p=0.996, t=0.005, df=34.0); pgm1-R64C (p=0.219, t=1.24, df=45.7); pgm1-T231A (p=0.077, t=1.84, df=36.4); pgm1Δ (p=0.003, t=3.12, df=45.7); pgm1-S120A (p<0.0001, t=4.45, df=38.6).

Figure 3 — figure supplement 4. Effects of pgm1 mutations on invertase glycosylation in the pACT1-sec53-V238M background. Western blot of invertase from reconstructed sec53/pgm1 strains.

Figure 3 — figure supplement 4 — source data 1. Raw images of blots and Ponceau stains.

Figure 3 — figure supplement 5. Effects of pgm1 mutations on invertase and CPY glycosylation in the pACT1-SEC53-WT background. Western blots of invertase and CPY from constructed SEC53/pgm1 strains.
Figure 3 — figure supplement 5 — source data 1. Raw images of blots and Ponceau stains.

Figure 3 — figure supplement 6. Effects of pgm1 mutations on invertase glycosylation in the pACT1-sec53-F126L background. Western blot of invertase from reconstructed sec53/pgm1 strains.

Figure 3 — figure supplement 6 — source data 1. Raw images of blots and Ponceau stains.

Figure 4. pgm1 mutations are dominant suppressors of sec53-V238M. (A) Diagram of possible spore genotypes in the tetrad dissections. Heterozygous (e.g. SEC53/sec53 PGM1/pgm1) diploid strains could produce one of three tetrad genotypes based on allele segregation. (B) Example of pgm1-T521K dissections in a sec53-V238M background (top) and a sec53-F126L background (bottom). Listed are the probability and log likelihood of suppression, based on the ratio of normal growth (large colonies) to slow growth (no colonies or small colonies). (C) Example of PGM1::pgm1-T521K dissections in a sec53-V238M background (top) and a sec53-F126L background (bottom). (D) Plot of recessive suppression versus dominant suppression of the pgm1 mutations in the sec53-V238M background (red circles) and sec53-F126L background (blue diamonds), based on the tetrad dissections.

Figure 4 — source data 1. Log likelihood analysis of tetrad dissections.

Figure 4 — figure supplement 1. Tetrad dissections of PGM1/pgm1 and ALG9/alg9 strains. 10 tetrads were dissected for each strain. Spores from the same tetrad are grouped vertically. The parental diploid strains contained heterozygous SEC53/sec53 alleles and heterozygous PGM1/pgm1 or ALG9/alg9 alleles.

Figure 4 — figure supplement 2. Tetrad dissections of PGM1-linked strains. 10 tetrads were dissected for each strain. Spores from the same tetrad are grouped vertically. The parental diploid strains contained heterozygous SEC53/sec53 alleles and 4 copies of PGM1; a wild-type copy of PGM1 was introduced next to the endogenous PGM1 ORF. Each haploid spore, then, contained either two wild-type copies (PGM1::PGM1) or a wild-type and mutant copy (PGM1::pgm1).

Figure 5. Complete loss of Pgm1 activity overshoots a fitness optimum. (A) AlphaFold structure of S. cerevisiae Pgm1 (Jumper et al., 2021). Mutated residues shown as spheres. (B) Kinetic parameters of recombinant Pgm1 enzymes as determined by a coupled enzymatic assay. Values ± 95% confidence intervals. (C) Michaelis-Menten curves of wild-type and mutant Pgm1. Replicate measurements are plotted as circles. (D) Pgm1 enzyme Vmax versus the corresponding allele’s fitness effect in the diploid pACT1-sec53-V238M background (as shown in Figure 3A). Horizontal and vertical error bars represent 95% confidence intervals. Best fit regression shown as a dashed curve (y=14.583+0.04613x-0.00014x^2, R^2=0.907, df=4, F=37.34, p=0.0258, ANOVA). Note that we did not measure Pgm1-S120A activity and assume null activity.

Figure 5 — source data 1. Other biochemical properties of mutant Pgm1.

Figure 5 — figure supplement 1. Enzymatic assays. Diagrams of the enzymatic reactions assayed in this study.
**Figure 5 — figure supplement 2. Thermostabilities of mutant Pgm1.** Average residual activity and standard deviations of recombinant Pgm1 enzymes determined after incubation at the conditions described on the x-axis. Replicate measurements plotted as gray circles. Proteins were incubated in the presence BSA (0.1 mg/ml).

**Figure 5 — figure supplement 3. Phosphomannomutase activity of mutant Pgm1.** (A) Representative phosphomannomutase assay by ³¹P-NMR spectroscopy. Pgm1 was incubated with 1mM M1P and 20 μM G16P for 0 or 60 minutes. The amount of M1P or M6P was measured by integrating the area of the signals and comparing them to creatine phosphate, added as an internal standard. (B) Spectrophotometric phosphoglucomutase assays were conducted at different concentrations of G1P and M1P. Shapes indicate varying concentrations of M1P and colors indicate Pgm1 variants.

**Figure 5 — figure supplement 4. pgm1 mutations increase glucose-1,6-bisphosphate levels in the pACT1-sec53-V238M background.** Average abundance and standard deviations of glucose-1,6-bisphosphate (G16P) in SEC53-WT and sec53-V238M strains following metabolite extraction. Plus signs (+) indicate wild-type alleles. Replicate measurements plotted as circles. Asterisks (*) represent statistically significant differences (Mann-Whitney U test, p<0.01).

**Figure 5 — figure supplement 5. Representative forward/reverse phosphoglucomutase assay.** Equal amounts of Pgm1 were incubated with G1P (A) or G6P (B) in the presence of G16P for 0, 5, 10, or 15 minutes. The amount of the substrates and products were measured by integrating the area of the signals and comparing them to creatine phosphate, added as an internal standard. Asterisks (*) indicate Pi contaminants.

**Supplementary File 1.** List of mutations that arose in the evolution experiment.

**Supplementary File 2.** Genotypes of strains used in this study.

**Supplementary File 3.** LOF/non-LOF Bayesian analysis.
### Table A

<table>
<thead>
<tr>
<th>Human Variant</th>
<th>Yeast Equivalent</th>
<th>Effect</th>
<th>Relative Enzyme Activity</th>
<th>Relative Growth Rate pSEC53 (1x)</th>
<th>pACT1 (2x)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PMM2</td>
<td>SEC53</td>
<td>Wild-type</td>
<td>1.00</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>pmm2-V231M</td>
<td>sec53-V238M</td>
<td>Decreased Stability</td>
<td>0.39</td>
<td>0.32</td>
<td>0.67</td>
</tr>
<tr>
<td>pmm2-F119L</td>
<td>sec53-F126L</td>
<td>Reduced Dimerization</td>
<td>0.25</td>
<td>0.27</td>
<td>0.57</td>
</tr>
</tbody>
</table>

### Diagram B

- **Inoculate**
- **Growth**
- **10 Generations**
- **1:1024 Dilution**

- pSEC53-sec53-V238M
- pACT1-sec53-V238M
- pACT1-sec53-F126L
- pSEC53-SEC53-WT
- pACT1-SEC53-WT

### Graph C

- pACT1-SEC53-WT
- pACT1-sec53-V238M
- pACT1-sec53-F126L
### A

#### Common targets of selection

- **Cell wall pathway**
- **Mating pathway**
- **Multidrug transport**
- **Ras pathway**

#### Targets of selection in sec53 evolution experiments

<table>
<thead>
<tr>
<th>Pathway</th>
<th>Number of Mutations</th>
<th>Populations Sequenced</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ras pathway</td>
<td>92</td>
<td>36</td>
</tr>
<tr>
<td>Mating pathway</td>
<td>43</td>
<td>40</td>
</tr>
<tr>
<td>Cell wall pathway</td>
<td>40</td>
<td>46</td>
</tr>
<tr>
<td>Multidrug transport</td>
<td>43</td>
<td>126</td>
</tr>
<tr>
<td>Type 1 CDG Homologs</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### B

<table>
<thead>
<tr>
<th>Genotype</th>
<th>Nuclear genes</th>
<th>Nonsynonymous mutations</th>
<th>Type 1 CDG genes</th>
<th>Type 1 CDG nonsynonymous mutations</th>
<th>Expected</th>
<th>Binomial Enrichment p-value</th>
<th>Binomial Depletion p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>pACT1-sec53-V238M</td>
<td>5,906</td>
<td>297</td>
<td>24</td>
<td>7</td>
<td>1.2</td>
<td><strong>0.00025</strong></td>
<td>0.99996</td>
</tr>
<tr>
<td>pACT1-sec53-F126L</td>
<td>5,906</td>
<td>178</td>
<td>24</td>
<td>1</td>
<td>0.7</td>
<td>0.52</td>
<td>0.99986</td>
</tr>
<tr>
<td>SEC53-WT</td>
<td>5,906</td>
<td>146</td>
<td>24</td>
<td>0</td>
<td>0.6</td>
<td>1</td>
<td>0.99998</td>
</tr>
<tr>
<td>Combined WT</td>
<td>5,906</td>
<td>9,933</td>
<td>24</td>
<td>20</td>
<td>40.4</td>
<td><strong>0.00025</strong></td>
<td>0.99996</td>
</tr>
</tbody>
</table>
A plot showing the fitness effect (%) of different genotypes in the context of carboxypeptidase Y glycosylation.

**pgm1 Δ/+S120A/+**

B: An overlay of SEC35 and PGM1 genotypes:

**SEC35**: +/+ V238M/V238M

**PGM1**: +/+ +/+ S120A/+R64C/+ S120A/+ R64C/+ 75 kDa

invertase mature under-glycosylated

kDa

mature under-glycosylated

75

75

50

37

37

carboxypeptidase Y
**SEC53**: +/+  
**V238M/V238M**

**PGM1**: +/+  
**S120A/S120A**  
**S120A/+**  
**pgm1Δ/pgm1Δ**  
**pgm1Δ/+**  
**R64C/+**  
**D295N/+**  
**G514C/+**

The image shows a gel electrophoresis with markers for kDa and invertase. The gel has bands indicating glycosylated and non-glycosylated forms of the protein.
SEC53: +/+  

PGM1: +/+  

**glycosylated forms**  
**non-glycosylated**  

**invertase**  

SEC53: +/+  

PGM1: +/+  

**mature**  
**under-glycosylated**  

**carboxypeptidase Y**
Genetic suppression of sec53

Dominant genetic suppression of sec53

Non-suppressors

Recessive suppressors

sec53-V238M background

sec53-F126L background

P \{\text{data | sup}\} = 4.2 \times 10^{-3}
P \{\text{data | ~sup}\} = 9.5 \times 10^{-31}
log likelihood = 27.6

P \{\text{data | sup}\} = 2.7 \times 10^{-4}
P \{\text{data | ~sup}\} = 9.5 \times 10^{-28}
log likelihood = 23.4

P \{\text{data | sup}\} = 4.0 \times 10^{-7}
P \{\text{data | ~sup}\} = 9.5 \times 10^{-25}
log likelihood = 17.6

P \{\text{data | sup}\} = 1.0 \times 10^{-10}
P \{\text{data | ~sup}\} = 9.6 \times 10^{-4}
log likelihood = -7.0

sec53-V238M background

sec53-F126L background

dominant suppressors

recessive suppressors

wt

T231A

R64C

S120A

G514C

T521K

D259N

pgm1Δ

wt

T231A

R64C

S120A

G514C

T521K

D259N

pgm1Δ

sec53 suppression of sec53

No suppression of sec53

Normal growth

Slow growth
<table>
<thead>
<tr>
<th>Gene</th>
<th>pACT1-SEC53-WT</th>
<th>pACT1-sec53-V238M</th>
<th>pACT1-sec53-F126L</th>
</tr>
</thead>
<tbody>
<tr>
<td>PGM1</td>
<td>![Image]</td>
<td>![Image]</td>
<td>![Image]</td>
</tr>
<tr>
<td>pgm1-T231A</td>
<td>![Image]</td>
<td>![Image]</td>
<td>![Image]</td>
</tr>
<tr>
<td>pgm1-G514C</td>
<td>![Image]</td>
<td>![Image]</td>
<td>![Image]</td>
</tr>
<tr>
<td>pgm1-T521K</td>
<td>![Image]</td>
<td>![Image]</td>
<td>![Image]</td>
</tr>
<tr>
<td>pgm1-R64C</td>
<td>![Image]</td>
<td>![Image]</td>
<td>![Image]</td>
</tr>
<tr>
<td>pgm1-D295N</td>
<td>![Image]</td>
<td>![Image]</td>
<td>![Image]</td>
</tr>
<tr>
<td>pgm1Δ</td>
<td>![Image]</td>
<td>![Image]</td>
<td>![Image]</td>
</tr>
<tr>
<td>pgm1-S120A</td>
<td>![Image]</td>
<td>![Image]</td>
<td>![Image]</td>
</tr>
<tr>
<td>alg9-S230R</td>
<td>![Image]</td>
<td>![Image]</td>
<td>![Image]</td>
</tr>
<tr>
<td>Protein</td>
<td>$V_{\text{max}}$ (U/mg)</td>
<td>$k_{\text{cat}}$ (s(^{-1}))</td>
<td>$K_M$ (μM)</td>
</tr>
<tr>
<td>---------------</td>
<td>--------------------------</td>
<td>-------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>Pgm1-WT</td>
<td>502 ± 26</td>
<td>528</td>
<td>37 ± 6</td>
</tr>
<tr>
<td>Pgm1-T231A</td>
<td>365 ± 21</td>
<td>384</td>
<td>27 ± 6</td>
</tr>
<tr>
<td>Pgm1-G514C</td>
<td>306 ± 15</td>
<td>322</td>
<td>67 ± 11</td>
</tr>
<tr>
<td>Pgm1-T521K</td>
<td>142 ± 13</td>
<td>149</td>
<td>78 ± 22</td>
</tr>
<tr>
<td>Pgm1-R64C</td>
<td>Not detectable</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Pgm1-D295N</td>
<td>Not detectable</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

![Diagram](image)
coupled spectrophotometric phosphoglucomutase assay

\[
glucose-1-phosphate \rightarrow^{phosphoglucomutase} glucose-6-phosphate \rightarrow^{glucose-6-phosphate dehydrogenase} 6-phosphogluconolactone
\]

+G16P

\[\text{NADP}^+ \rightarrow \text{NADPH}\]

31P-NMR phosphomannomutase assay

\[
mannose-1-phosphate \rightarrow^{phosphomannomutase} mannose-6-phosphate
\]

+G16P

coupled spectrophotometric bisphosphatase assay

\[
glucose-1,6-bisphosphate + Pgm1 \rightarrow^{phosphorylated Pgm1} glucose-6-phosphate + phosphorylated Pgm1
\]

\[
\text{glucose-6-phosphate dehydrogenase} \rightarrow 6-phosphogluconolactone
\]

\[
glucose-1-phosphate + phosphorylated Pgm1 \rightarrow Pgm1 + P_i\]

\[\text{H}_2\text{O}\]

31P-NMR phosphoglucomutase assay

\[
glucose-1-phosphate \rightarrow^{phosphoglucomutase} glucose-6-phosphate
\]

forward

reverse

+G16P
Intracellular Glucose-1,6-Bisphosphate (pmol/million cells)

**PGM1 Genotype**

- **+/+**
- **T521K/+**
- **D295N/+**

**pACT1-SEC53-WT background**

- **NS**

**pACT1-sec53-V238M background**

- **NS**
- *****

Legend:

- **+**
- **+**
- **+**

Notes:

- **NS**
- *****

Graph shows comparison of intracellular glucose-1,6-bisphosphate levels across different genotypes in two different backgrounds.